




ENGOT Ov-17 Trial MITO 16b; MANGO-OV2b



A multicenter phase III randomized study with second line chemotherapy ± bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first line
ARM 1: 6 cycles

- Ovarian Ca
- Platinum-sensitive
- Previous Bevacizumab
- ECOG 0-2
- Availability of samples for translational res.
- No Beva contraindications



CBDCA AUC5 + PAC 175 mg/m² q3w
or
CBDCA AUC4, d1 + GEM 1000mg /m², d1&8 q3w
or
CBDCA AUC5+PLD 30mg/m² q4w

ARM 2*: 6 cycles

CBDCA AUC5 + PAC 175 mg/m² q3w
Plus bevacizumab 15mg/kg q3w**
or
CBDCA AUC4, d1 + GEM 1000mg /m², d1&8 q3w
Plus bevacizumab 15mg/kg q3w
or
CBDCA AUC5+PLD 30mg/m² q4w
Plus bevacizumab 10mg/kg q2w



ENGOT Ov-17 Trial MITO 16b; MANGO-OV2b



A multicenter phase III randomized study with second line chemotherapy ± bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first line

Sponsor: NCI Naples

Lead groups: MITO MaNGO

Planned No. of patients: 400

No. of already recruited patients: 85

Timeline: LPI Q4 2016

Enrollment by Group

GROUP	N. Patients
MITO	194
GINECO	100
MANGO	63
SAKK	17
HeCOG	11
BGOG	0
Total	385